Skip to content

Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion

Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00466999
Enrollment
1000
Registered
2007-04-27
Start date
2007-02-28
Completion date
2009-11-30
Last updated
2012-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incomplete Abortion

Keywords

misoprostol, incomplete abortion, PAC

Brief summary

In this study, we will compare the safety and efficacy of 400 mcg sublingually administered misoprostol alone to standard surgical care for the treatment of incomplete abortion. This study will provide important data on the role of misoprostol in health services offering an array of treatments for incomplete abortion. Women could significantly benefit from a non-invasive treatment option for incomplete abortion. While safe surgical services are becoming more widespread, there is still a serious risk of complications from these procedures. Especially in developing countries, infection, hemorrhage and uterine damage are still too common. Medical treatment of incomplete abortion using misoprostol would be a tremendous step to reducing morbidity and mortality due to abortion complications.

Interventions

DRUGmisoprostol

single dose of 400 mcg misoprostol administered sublingually

PROCEDUREsurgery

standard surgical treatment (dilation and curettage or manual vacuum aspiration)

Sponsors

Gynuity Health Projects
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* Uterine size no larger than 12 weeks LMP at time of presentation for care. * Past or present history of vaginal bleeding during pregnancy. * Open cervical os. * If ultrasound used evidence of incomplete abortion with substantial debris in the uterus. * All women would have been advised to have surgical evacuation of the uterus if misoprostol was not available. * General good health. * Willing to provide contact information for purposes of follow-up. * Also in Egypt: 21 years of age or over or parental permission (there is no minimum age requirement in Niger, Mauritania and Senegal).

Exclusion criteria

* Contraindications to study drug * Signs of severe infection, defined as at least one of the following: 1) foul smelling discharge, 2) fever \> 38 degrees C , 3) uterine tenderness * Hemodynamic disturbances (pulse \>110/min and systolic bp \<100) * Have an IUD in place; (the IUD may be removed making the woman eligible) * Suspected ectopic pregnancy

Design outcomes

Primary

MeasureTime frame
Complete abortion without recourse to surgical intervention.follow up visit 7 days after initial treatment

Countries

Burkina Faso, Egypt, Mauritania, Niger, Senegal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026